Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.44 |
| ▸ | BRAF | P15056 | 7/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199859 | 0.89 | BRAF (0.43) | KDRBRAF | |
| SCHEMBL545910 | 0.88 | MAPT (0.44) | KDR | |
| SCHEMBL10199818 | 0.85 | DDR2 (0.55) | KDRBRAFCSF1RDDR2FGFR1 | |
| SCHEMBL545887 | 0.84 | KDR (0.51) | KDRBRAFFGFR1SYK | |
| SCHEMBL10199786 | 0.82 | KDR (0.51) | KDRBRAFFGFR1 | |
| SCHEMBL10199947 | 0.79 | BRAF (0.47) | KDRBRAF | |
| SCHEMBL10199956 | 0.78 | RAF1 (0.49) | KDRBRAF | |
| SCHEMBL10199733 | 0.78 | KDR (0.42) | KDRBRAF | |
| SCHEMBL545637 | 0.78 | KDR (0.52) | KDRBRAFCSF1RDDR2GSK3B | |
| SCHEMBL545010 | 0.76 | KDR (0.50) | KDRBRAFCSF1RDDR2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | KDR 1264/4885BRAF 215/4885CSF1R 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.